OP024 BODY COMPOSITION AS A PREDICTOR OF DOSE LIMITING CHEMOTHERAPY TOXICITY IN PATIENTS WITH RENAL CELL CARCINOMA

Autor: R. McDermott, Derek G. Power, S. Cushen, Peter Mceneaney, P. McLaughlin, M. Teo, Aoife M. Ryan, F. Fitzpatrick
Rok vydání: 2013
Předmět:
Zdroj: Clinical Nutrition. 32:S10
ISSN: 0261-5614
DOI: 10.1016/s0261-5614(13)60026-6
Popis: of a potential role of n-3FA in treatment of cancer requires regular long-term administration. Methods: As part of a phase II trial in patients with advanced pancreatic cancer, up to 100 g of n-3FA (Lipidem, BBraun, Melsungen) was administered with gemcitabine chemotherapy weekly, with a rest every fourth week for up to six months. Pre-treatment serum and erythrocyte cell membrane (ECM) pellet samples were obtained for the entire treatment course of each patient. Post-treatment samples were obtained for the first two cycles only to assess rapid uptake. Fatty acid methyl esters (FAME) were produced by gas chromatography and their proportions as a total of sample lipid composition analysed using a mixed effects linear regression model. Results: Twenty nine patients were evaluated with median treatment length of 3.5 months (range 0 6 months). Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) FAMEs showed rapid uptake into plasma, and EPA into ECM pellets in post-treatment samples (p = 0.03). There was significant sustained uptake of EPA and DHA FAMEs into ECM pellets over the cohort’s pooled treatment course (p < 0.001 and p = 0.04 respectively) with corresponding reduction in the n6:n3 ratio (p = 0.007). Conclusion: Parenteral n-3FA administered in weekly highdose rate regimens results in rapid and sustained cellular uptake over a period of up to six months. This regimen is appropriate for therapies aimed at increasing n-3FA content of cellular membranes and reduction of the n6:n3 ratio.
Databáze: OpenAIRE
Externí odkaz: